--- title: "Semaglutide: Dosing & Vendor Prices | BodyHackGuide" url: https://www.bodyhackguide.co/compound/semaglutide description: "Semaglutide: dosing protocols, mechanism & side effects, 3,273 PubMed results. Compare 6 current vendor prices." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Image: Semaglutide molecular structure (https://www.bodyhackguide.co/assets/peptide-structure-placeholder-DUmZBF_j.png) # Semaglutide Metabolic & Weight Loss (https://www.bodyhackguide.co/wiki#cat-metabolic-&-weight-loss)FDA Approved Also known as: GLP-1S, GLP-1 Agonist, RC-1S, PEP-1S, ION-1S, Ion Peptide Semaglutide, GLP-1, Semaglutide, Sema Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2. It is a 31-amino-acid peptide analog of human GLP-1(7-37) with two key structural modifications: an alpha-aminoisobutyric acid (Aib) substitution at position 8 that confers resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, and a C18 fatty diacid chain attached via a linker at position 26 (lysine) that enables non-covalent binding to serum albumin. R Featured vendor $5.83/mg $174.99 for 30mg at ResearchChemHQ · Buy at RC: https://researchchemhq.co/product/rc-1s/?ref=oyxnywoz Half-life: ~7 days (168 hours), enabled by C18 fatty diacid albumin-bind… Route: Subcutaneous (weekly), Oral (daily) MW: 4113.6 Da CAS: 910463-68-2 3,273 PubMed results (https://pubmed.ncbi.nlm.nih.gov/?term=semaglutide%20GLP-1) Last reviewed: May 4, 2026 Reconstitution Calculator for Semaglutide Pre-filled · 5mg vial · 250mcg dose https://www.bodyhackguide.co/tools/reconstitution/semaglutide ## Overview ### At A Glance Mechanism GLP-1 Receptor Agonism and cAMP Signaling… Half-Life ~7 days (168 hours), enabled by C18 fatty diacid albumin-binding modification Dosing Once weekly subcutaneous injection Dose Range Diabetes (Ozempic): 250-1000 mcg weekly; Weight management (Wegovy): 2400 mcg weekly (after 16-week titration); Oral (Rybelsus): 3-14 mg daily Routes Subcutaneous (weekly) Oral (daily) Common Vials 3mg 5mg 10mg Potential Benefits Mean body weight reduction of 14.9% at 68 weeks in STEP 1 trial (PMID: 33567185) Sustained weight loss of ~15% (-15.2%) maintained through 104 weeks in STEP 5 trial (PMID: 36216945) 20% relative reduction in major adverse cardiovascular events (HR 0.80) in the SELECT trial (PMID: 37952131) HbA1c reduction of 1.5-1.8% in type 2 diabetes (SUSTAIN program) Reduction in systemic inflammation (lower hs-CRP) observed in SELECT Available in both subcutaneous (weekly) and oral (daily) formulations Improved cardiometabolic risk factors including blood pressure and lipid profile Safety Notes Common Nausea (most common, affects 20-44% of patients, dose-dependent) Vomiting (typically during dose titration, resolves with continued use) Diarrhea and constipation Abdominal pain and dyspepsia Injection site reactions (subcutaneous formulation) Serious Pancreatitis (rare but reported — discontinue if suspected) Gallbladder disorders including cholelithiasis (gallstones) with rapid weight loss Medullary thyroid carcinoma (MTC) risk — boxed warning based on rodent thyroid C-cell tumors Acute kidney injury (dehydration-mediated, usually from severe GI side effects) Diabetic retinopathy worsening with rapid glycemic improvement in T2D patients Suicidal ideation (rare post-marketing reports under FDA review) ### Overview Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2. It is a 31-amino-acid peptide analog of human GLP-1(7-37) with two key structural modifications: an alpha-aminoisobutyric acid (Aib) substitution at position 8 that confers resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, and a C18 fatty diacid chain attached via a linker at position 26 (lysine) that enables non-covalent binding to serum albumin. This albumin binding dramatically extends the half-life to approximately 7 days, enabling once-weekly subcutaneous dosing (PMID: 33567185). Semaglutide is FDA-approved under three brand names: Ozempic (subcutaneous injection for type 2 diabetes mellitus), Wegovy (subcutaneous injection for chronic weight management), and Rybelsus (oral tablet for type 2 diabetes). Ozempic was approved in 2017, Wegovy in 2021, and Rybelsus in 2019, making semaglutide one of the most commercially significant pharmaceutical developments of the 2020s. The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program established semaglutide as a transformative obesity treatment. In the STEP 1 trial, participants receiving semaglutide 2.4 mg weekly achieved a mean body weight reduction of 14.9% from baseline at 68 weeks, compared to 2.4% with placebo — a treatment difference of 12.4 percentage points (PMID: 33567185). The STEP 5 trial demonstrated durability of weight loss with continued treatment over 104 weeks, with participants maintaining approximately 15% total body weight loss (PMID: 34170647). The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial was a landmark cardiovascular outcomes study that demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE — cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in overweight or obese individuals without diabetes who received semaglutide 2.4 mg weekly versus placebo over a median follow-up of 39.8 months (PMID: 37351564). This was the first trial to demonstrate cardiovascular benefit of a weight management drug in a non-diabetic population, fundamentally changing the clinical paradigm around obesity pharmacotherapy. Oral semaglutide (Rybelsus) uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) to enable GI absorption of the peptide. Despite low bioavailability (~1%), the oral formulation achieves clinically meaningful glycemic control in type 2 diabetes. Higher-dose oral semaglutide (25 mg and 50 mg) formulations evaluated in the OASIS program have shown weight loss approaching that of subcutaneous semaglutide. Semaglutide represents a first-in-class efficacy level among GLP-1 receptor agonists for both glycemic control and weight reduction, with a well-characterized safety profile across tens of thousands of clinical trial participants and millions of post-marketing prescriptions. ### Potential Research Fields Obesity Type 2 diabetes Cardiovascular disease NASH/MAFLD Kidney disease ## Chemical Information IUPAC Name N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetamido]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37)-peptide CAS Number 910463-68-2 Molecular Formula C187H291N45O59 Molecular Mass 4113.58 g/mol Image: Semaglutide molecular structure (https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/56843326/PNG?image_size=300x300) View on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/56843326 Amino Acid Sequence HXEGTFTSDVSSYLEGQAAKEFIAWLVRGRG (31-residue analog of human GLP-1(7-37); X at position 8 = Aib, 2-aminoisobutyric acid). Key modifications vs native GLP-1: Ala8->Aib (confers DPP-4 resistance), Lys34->Arg, and the Lys26 side chain is acylated with a C18 fatty diacid (octadecanedioic acid) via a gamma-Glu / 2x AEEA (8-amino-3,6-dioxaoctanoic acid) linker, enabling strong albumin binding and a ~1-week half-life. Molecular formula C187H291N45O59; average molecular weight ~4113.6 Da. ## Dosing & Protocols ### Unlock the dosing protocols Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser. - Dose, route, how often and how long - A titration schedule - Beginner, intermediate and advanced protocols - Reconstitution and handling notes You also get the free peptide cheat sheet by email. Unsubscribe anytime. Have an account? Sign in (https://www.bodyhackguide.co/auth) ## Research ### Unlock the research summary - A summary of the key research - Safety and side effects - A link to the PubMed results ## Interactions ### Interaction Matrix ### Contraindications Personal or family history of medullary thyroid carcinoma (MTC). Multiple endocrine neoplasia syndrome type 2 (MEN 2). History of pancreatitis. Severe gastrointestinal disease. Type 1 diabetes. Pregnancy or breastfeeding. Eating disorders (may exacerbate restriction). Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $39.00 up to $174.99 Best $/mg $3.3000 Vendors 6 Listings 13 vial, pen Dosage Form Sort | Vendor | Product | Form | Qty | Price | $/mg | Coupon | | | --- | --- | --- | --- | --- | --- | --- | --- | | Image: ResearchChemHQ logo (https://staging.researchchemhq.co/wp/wp-content/uploads/2024/08/cropped-RCHQ-Invert-Logo-e1724477505900.png) ResearchChemHQ (https://www.bodyhackguide.co/vendors/researchchemhq) 100: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US | RC-1S 30mg | vial | 30mg vial ● In Stock | $174.99 | $5.83 | REDDIT | Buy: https://researchchemhq.co/product/rc-1s/?ref=oyxnywoz | | Image: Disguised Alpha logo (https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha (https://www.bodyhackguide.co/vendors/disguised-alpha) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🇪🇺 EU 🇬🇧 UK | Semaglutide | vial | 1 vial ● In Stock | $64.99 | — | — | Buy: https://disguisedalpha.com/product/semaglutide/?coupon=reddit | | Image: Disguised Alpha logo (https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha (https://www.bodyhackguide.co/vendors/disguised-alpha) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🇪🇺 EU 🇬🇧 UK | Semaglutide Pen 10 mg | pen | 1 pen ● In Stock | $139.99 | $14.00 | — | Buy: https://disguisedalpha.com/product/semaglutidepen/?coupon=reddit | | Image: Optimum Formula logo (https://optimumformula.co/wp-content/uploads/2025/07/LOGO-OPTIMUM-NEW.png) Optimum Formula (https://www.bodyhackguide.co/vendors/optimum-formula) 100: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US | Pep-1S 5mg (Semaglutide) | vial | 5mg ● In Stock | $59.99 | $12.00 | REDDIT | Buy: https://optimumformula.co/product/pep-1s/?ref=ruyhjwqh | | Image: Optimum Formula logo (https://optimumformula.co/wp-content/uploads/2025/07/LOGO-OPTIMUM-NEW.png) Optimum Formula (https://www.bodyhackguide.co/vendors/optimum-formula) 100: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US | Pep-1S 30mg (Semaglutide) | vial | 1 vial ● In Stock | $174.99 | $5.83 | REDDIT | Buy: https://optimumformula.co/product/pep-1s/?ref=ruyhjwqh | | Image: Ion Peptide logo (https://ionpeptide.com/wp-content/uploads/2025/08/ion-peptide-logo-1-300x148.jpg) Ion Peptide (https://www.bodyhackguide.co/vendors/ion-peptide) 70: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🌍 International | Semaglutide (ION-1S) 5mg | vial | 1 vial ● In Stock | $39.00 BEST | $7.80 | — | Buy: https://ionpeptide.com/product/glp-1s/?ref=reddit15 | | Image: Ion Peptide logo (https://ionpeptide.com/wp-content/uploads/2025/08/ion-peptide-logo-1-300x148.jpg) Ion Peptide (https://www.bodyhackguide.co/vendors/ion-peptide) 70: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🌍 International | Semaglutide (ION-1S) 10mg | vial | 1 vial ● In Stock | $55.00 | $5.50 | — | Buy: https://ionpeptide.com/product/glp-1s/?ref=reddit15 | | Image: Ion Peptide logo (https://ionpeptide.com/wp-content/uploads/2025/08/ion-peptide-logo-1-300x148.jpg) Ion Peptide (https://www.bodyhackguide.co/vendors/ion-peptide) 70: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🌍 International | Semaglutide (ION-1S) 20mg | vial | 1 vial ● Out of Stock | $69.00 | $3.45 | — | View: https://ionpeptide.com/product/glp-1s/?ref=reddit15 | | Image: Ion Peptide logo (https://ionpeptide.com/wp-content/uploads/2025/08/ion-peptide-logo-1-300x148.jpg) Ion Peptide (https://www.bodyhackguide.co/vendors/ion-peptide) 70: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🌍 International | Semaglutide (ION-1S) 30mg | vial | 1 vial ● In Stock | $99.00 VALUE | $3.30 | — | Buy: https://ionpeptide.com/product/glp-1s/?ref=reddit15 | | Image: BioMyst Labs logo (https://biomystlabs.com/wp-content/uploads/2025/12/Asset-36@3x-scaled.png) BioMyst Labs (https://www.bodyhackguide.co/vendors/biomyst-labs) 70: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US 🌍 International | Semaglutide 5mg | vial | 5mg ● In Stock | $94.99 | $19.00 | — | Buy: https://biomystlabs.com/product/semaglutide-5mg/?ref=rxtkqorwv | | Image: VANDL Labs logo (https://halfnattys.shop/wp-content/themes/halfnattys/assets/img/logo.webp) VANDL Labs (https://www.bodyhackguide.co/vendors/vandl-labs) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US | GLP-1S (Semaglutide) 2mg | vial | 2mg vial ● In Stock | $69.99 | $34.99 | CHON | Buy: https://www.vandl-labs.com/product/glp-1s/?ref=choncho | | Image: VANDL Labs logo (https://halfnattys.shop/wp-content/themes/halfnattys/assets/img/logo.webp) VANDL Labs (https://www.bodyhackguide.co/vendors/vandl-labs) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US | GLP-1S (Semaglutide) 5mg | vial | 5mg vial ● In Stock | $99.99 | $20.00 | CHON | Buy: https://www.vandl-labs.com/product/glp-1s/?ref=choncho | | Image: VANDL Labs logo (https://halfnattys.shop/wp-content/themes/halfnattys/assets/img/logo.webp) VANDL Labs (https://www.bodyhackguide.co/vendors/vandl-labs) 50: https://www.bodyhackguide.co/vendor-trust-scorecard 🇺🇸 US | GLP-1S (Semaglutide) 10mg | vial | 10mg vial ● In Stock | $159.99 | $16.00 | CHON | Buy: https://www.vandl-labs.com/product/glp-1s/?ref=choncho | ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Semaglutide. Current low $39.00 current listings 7-day low — not enough history yet 30-day low — not enough history yet 30-day change — not enough history yet Tracking since Mar 13, 2026 · 12 data points ## Price History 4 data points ### Vendors Selling Semaglutide #### Ion Peptide 4.5 4 listings · from $39.00 https://www.bodyhackguide.co/vendors/ion-peptide #### Optimum Formula 4.9 2 listings · from $59.99 https://www.bodyhackguide.co/vendors/optimum-formula #### Disguised Alpha 2 listings · from $64.99 https://www.bodyhackguide.co/vendors/disguised-alpha #### VANDL Labs 3 listings · from $69.99 https://www.bodyhackguide.co/vendors/vandl-labs #### BioMyst Labs 4.5 1 listing · from $94.99 https://www.bodyhackguide.co/vendors/biomyst-labs #### ResearchChemHQ 4.7 1 listing · from $174.99 https://www.bodyhackguide.co/vendors/researchchemhq How we score these vendors Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. View Scorecard (https://www.bodyhackguide.co/vendors/scorecard) ### Related Compounds View All (https://www.bodyhackguide.co/wiki) ### AOD-9604 Metabolic & Weight Loss Phase 3 AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide fragment of human growth hormone (hGH) corresponding to residues 177-191 of the hGH molecule plus a tyrosine addition at the N-terminus (sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe). t½ ~30–60 minutes 250–600 mcg per injection 1 PubMed View Profile https://www.bodyhackguide.co/compound/aod-9604 ### ATX-304 Metabolic & Weight Loss Phase IIa Clinical Trials ATX-304 (also known as O-304) is an orally bioavailable, first-in-class pan-AMPK activator with a mild mitochondrial-uncoupling effect. Preclinical View Profile https://www.bodyhackguide.co/compound/atx-304 ### Cagrilintide Metabolic & Weight Loss Phase 3 Cagrilintide (also known as AM833, development code NN9838) is a long-acting amylin analog developed by Novo Nordisk as a next-generation weight-management therapy, designed to be co-administered with the GLP-1 receptor agonist semaglutide in a fixed-ratio combination known as CagriSema. t½ ~159 hours (approximately 7 days) 46 PubMed View Profile https://www.bodyhackguide.co/compound/cagrilintide ### HGH Fragment 176-191 Metabolic & Weight Loss Phase 2 HGH Fragment 176-191 (also written HGH Frag 176-191, hGH Fragment 176-191, and frequently appearing in clinical literature as AOD-9604 — "Anti-Obesity Drug 9604") is a synthetic peptide corresponding to the C-terminal 15-amino-acid region of the 191-amino-acid human growth hormone (hGH) molecule, with an additional N-terminal tyrosine residue added for stability and biological activity. t½ ~30 minutes (short plasma half-life) 250-500 mcg 2 PubMed View Profile https://www.bodyhackguide.co/compound/hgh-frag-176-191 ### Retatrutide Metabolic & Weight Loss Phase 3 Retatrutide (also coded LY3437943) is an investigational once-weekly triple-agonist at the GLP-1, GIP, and glucagon receptors. t½ ~6 days (plasma, albumin-bound) 1,000–12,000 mcg (1–12 mg) per week 135 PubMed View Profile https://www.bodyhackguide.co/compound/retatrutide ### Tirzepatide Metabolic & Weight Loss FDA Approved Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. t½ ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose 626 PubMed View Profile https://www.bodyhackguide.co/compound/tirzepatide ### Side-by-Side Comparisons All Comparisons (https://www.bodyhackguide.co/compare) Semaglutide vs Tirzepatide: https://www.bodyhackguide.co/compare/tirzepatide-vs-semaglutide Semaglutide vs Retatrutide: https://www.bodyhackguide.co/compare/retatrutide-vs-semaglutide Semaglutide vs Orforglipron: https://www.bodyhackguide.co/compare/orforglipron-vs-semaglutide Semaglutide vs AOD-9604: https://www.bodyhackguide.co/compare/aod-9604-vs-semaglutide View Full Dosage Guide → Protocols, calculator & safety for Semaglutide https://www.bodyhackguide.co/guides/dosage/semaglutide ### Related Articles All Posts (https://www.bodyhackguide.co/blog) #### The 8 Best Peptide Companies for Research: 2026 Purity & Price Comparison A data-driven comparison of every active peptide vendor we track: COA audit results, price-per-mg tables for 19 compounds, and a step-by-step purchase guide. 9/16/2026 https://www.bodyhackguide.co/blog/best-peptide-companies-2026 #### Myostatin: The Muscle Brake, the Inhibitors, and What Actually Works (2026) Myostatin is your body's brake on muscle growth. The famous mutations, the inhibitor drugs (apitegromab, bimagrumab) and their honest trial record, the supplement hype, and how to keep muscle on a GLP-1. 7/9/2026 https://www.bodyhackguide.co/blog/myostatin-and-muscle #### Aquasome Nanotechnology and Oral Peptides: The Mechanism, the Research, and the 10 Compounds It Actually Works For how aquasome 3-layer nano-encapsulation lets peptides like retatrutide, bpc-157, and tb-500 survive the gut. pubmed-backed deep dive on the 10 compounds it works for. 5/20/2026 https://www.bodyhackguide.co/blog/aqasome-nanotechnology-oral-peptides ### Featured Price ⚗️ ResearchChemHQ $174.99($5.83/mg) 6 vendors · 13 listings ### Research Score 100 3,273 PubMed results ### Quality Indicators Data Completeness 100% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Results Interactions Vendor Listings COA Verification 10 Verified COAs 2 Vendors w/ COA High verification rate (83%) Latest test: 3/1/2026 Research Volume 3,273 PubMed results Well-researched compound ### Quick Facts Half-Life Molecular Weight 4113.58 g/mol Administration Subcutaneous (weekly), Oral (daily) CAS Number 910463-68-2 Trial Phase FDA Approved ### Safety Profile Common Side Effects - • Nausea (most common, affects 20-44% of patients, dose-dependent) - • Vomiting (typically during dose titration, resolves with continued use) - • Diarrhea and constipation - • Abdominal pain and dyspepsia - • Injection site reactions (subcutaneous formulation) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions How is semaglutide dosed for weight loss? The Wegovy schedule climbs once a week: 0.25 mg for the first four weeks, then 0.5, 1, 1.7, and 2.4 mg as the maintenance dose, moving up about every four weeks. The 0.25 mg start is there to settle your stomach, not to drive results. Move up only once side effects calm down. What is the difference between Ozempic and Wegovy? Same drug, semaglutide, with different branding and approved doses. Ozempic is the type-2-diabetes brand; Wegovy is the weight-management brand and goes to a higher 2.4 mg dose. The molecule is identical. Why does semaglutide cause nausea? GLP-1 drugs slow how fast your stomach empties, which is part of how they curb appetite, and that is what drives the nausea. It is dose-related and usually fades. Titrating up slowly is the main way to keep it manageable. ## Research Tools ### Peptide Calculator Reconstitution & syringe units https://www.bodyhackguide.co/tools/reconstitution ### Reconstitution Guide How to mix, step by step https://www.bodyhackguide.co/guides/how-to-reconstitute-peptides ### Nasal Spray Calc mL per actuation https://www.bodyhackguide.co/tools/intranasal ### Half-Life Visualizer Decay curves https://www.bodyhackguide.co/tools/halflife ## Related Compounds ### AOD-9604 Metabolic & Weight Loss Phase 3 ### ATX-304 ### Cagrilintide Metabolic & Weight Loss Phase 3 t½ ~159 hours (approximately 7 days) ### HGH Fragment 176-191 Metabolic & Weight Loss Phase 2 ### Retatrutide Metabolic & Weight Loss Phase 3 ### Tirzepatide Metabolic & Weight Loss FDA Approved ## Side-by-Side Comparisons Compare Semaglutide head-to-head: mechanism, half-life, dosing, safety, and vendor prices. Free 2026 Peptide Cheat Sheet (PDF) 38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers. Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Semaglutide" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "Semaglutide", "description": "Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2. It is a 31-amino-acid peptide analog of human GLP-1(7-37) with two key structural modifications: an alpha-aminoisobutyric acid (Aib) substitution at position 8 that confers resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, and a C18 fatty diacid chain attached via a linker at position 26 (lysine) that enables non-covalent binding to serum albumin. This albumin binding dramatically extends the half-life to approximately 7 days, enabling once-weekly subcutaneous dosing (PMID: 33567185). Semaglutide is FDA-approved under three brand names: Ozempic (subcutaneous injection for type 2 diabetes mellitus), Wegovy (subcutaneous injection for chronic weight management), and Rybelsus (oral tablet for type 2 diabetes). Ozempic was approved in 2017, Wegovy in 2021, and Rybelsus in 2019, making semaglutide one of the most commercially significant pharmaceutical developments of the 2020s. The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program established semaglutide as a transformative obesity treatment. In the STEP 1 trial, participants receiving semaglutide 2.4 mg weekly achieved a mean body weight reduction of 14.9% from baseline at 68 weeks, compared to 2.4% with placebo — a treatment difference of 12.4 percentage points (PMID: 33567185). The STEP 5 trial demonstrated durability of weight loss with continued treatment over 104 weeks, with participants maintaining approximately 15% total body weight loss (PMID: 34170647). The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial was a landmark cardiovascular outcomes study that demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE — cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in overweight or obese individuals without diabetes who received semaglutide 2.4 mg weekly versus placebo over a median follow-up of 39.8 months (PMID: 37351564). This was the first trial to demonstrate cardiovascular benefit of a weight management drug in a non-diabetic population, fundamentally changing the clinical paradigm around obesity pharmacotherapy. Oral semaglutide (Rybelsus) uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) to enable GI absorption of the peptide. Despite low bioavailability (~1%), the oral formulation achieves clinically meaningful glycemic control in type 2 diabetes. Higher-dose oral semaglutide (25 mg and 50 mg) formulations evaluated in the OASIS program have shown weight loss approaching that of subcutaneous semaglutide. Semaglutide represents a first-in-class efficacy level among GLP-1 receptor agonists for both glycemic control and weight reduction, with a well-characterized safety profile across tens of thousands of clinical trial participants and millions of post-marketing prescriptions.", "url": "https://www.bodyhackguide.co/compound/semaglutide", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "39.00", "highPrice": "174.99", "priceCurrency": "USD", "offerCount": "12", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "39.00", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://ionpeptide.com/product/glp-1s/?ref=reddit15", "seller": { "@type": "Organization", "name": "Ion Peptide", "url": "https://ionpeptide.com" }, "name": "Semaglutide 5mg vial" }, { "@type": "Offer", "price": "55.00", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://ionpeptide.com/product/glp-1s/?ref=reddit15", "seller": { "@type": "Organization", "name": "Ion Peptide", "url": "https://ionpeptide.com" }, "name": "Semaglutide 10mg vial" }, { "@type": "Offer", "price": "59.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://optimumformula.co/product/pep-1s/?ref=ruyhjwqh", "seller": { "@type": "Organization", "name": "Optimum Formula", "url": "https://optimumformula.co" }, "name": "Semaglutide 5mg vial" }, { "@type": "Offer", "price": "64.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/semaglutide/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } }, { "@type": "Offer", "price": "69.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://www.vandl-labs.com/product/glp-1s/?ref=choncho", "seller": { "@type": "Organization", "name": "VANDL Labs", "url": "https://www.vandl-labs.com/?ref=choncho" }, "name": "Semaglutide 2mg vial" }, { "@type": "Offer", "price": "94.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://biomystlabs.com/product/semaglutide-5mg/?ref=rxtkqorwv", "seller": { "@type": "Organization", "name": "BioMyst Labs", "url": "https://biomystlabs.com" }, "name": "Semaglutide 5mg vial" }, { "@type": "Offer", "price": "99.00", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://ionpeptide.com/product/glp-1s/?ref=reddit15", "seller": { "@type": "Organization", "name": "Ion Peptide", "url": "https://ionpeptide.com" }, "name": "Semaglutide 30mg vial" }, { "@type": "Offer", "price": "99.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://www.vandl-labs.com/product/glp-1s/?ref=choncho", "seller": { "@type": "Organization", "name": "VANDL Labs", "url": "https://www.vandl-labs.com/?ref=choncho" }, "name": "Semaglutide 5mg vial" }, { "@type": "Offer", "price": "139.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/semaglutidepen/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" }, "name": "Semaglutide 10mg pen" }, { "@type": "Offer", "price": "159.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://www.vandl-labs.com/product/glp-1s/?ref=choncho", "seller": { "@type": "Organization", "name": "VANDL Labs", "url": "https://www.vandl-labs.com/?ref=choncho" }, "name": "Semaglutide 10mg vial" }, { "@type": "Offer", "price": "174.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://optimumformula.co/product/pep-1s/?ref=ruyhjwqh", "seller": { "@type": "Organization", "name": "Optimum Formula", "url": "https://optimumformula.co" }, "name": "Semaglutide 30mg vial" }, { "@type": "Offer", "price": "174.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://researchchemhq.co/product/rc-1s/?ref=oyxnywoz", "seller": { "@type": "Organization", "name": "ResearchChemHQ", "url": "https://researchchemhq.co/?ref=oyxnywoz" }, "name": "Semaglutide 30mg vial" } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Semaglutide", "description": "Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2. It is a 31-amino-acid peptide analog of human GLP-1(7-37) with two key structural modifications: an alpha-aminoisobutyric acid (Aib) substitution at position 8 that confers resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, and a C18 fatty diacid chain attached via a linker at position 26 (lysine) that enables non-covalent binding to serum albumin. This albumin binding dramatically extends the half-life to approximately 7 days, enabling once-weekly subcutaneous dosing (PMID: 33567185). Semaglutide is FDA-approved under three brand names: Ozempic (subcutaneous injection for type 2 diabetes mellitus), Wegovy (subcutaneous injection for chronic weight management), and Rybelsus (oral tablet for type 2 diabetes). Ozempic was approved in 2017, Wegovy in 2021, and Rybelsus in 2019, making semaglutide one of the most commercially significant pharmaceutical developments of the 2020s. The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program established semaglutide as a transformative obesity treatment. In the STEP 1 trial, participants receiving semaglutide 2.4 mg weekly achieved a mean body weight reduction of 14.9% from baseline at 68 weeks, compared to 2.4% with placebo — a treatment difference of 12.4 percentage points (PMID: 33567185). The STEP 5 trial demonstrated durability of weight loss with continued treatment over 104 weeks, with participants maintaining approximately 15% total body weight loss (PMID: 34170647). The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial was a landmark cardiovascular outcomes study that demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE — cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in overweight or obese individuals without diabetes who received semaglutide 2.4 mg weekly versus placebo over a median follow-up of 39.8 months (PMID: 37351564). This was the first trial to demonstrate cardiovascular benefit of a weight management drug in a non-diabetic population, fundamentally changing the clinical paradigm around obesity pharmacotherapy. Oral semaglutide (Rybelsus) uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) to enable GI absorption of the peptide. Despite low bioavailability (~1%), the oral formulation achieves clinically meaningful glycemic control in type 2 diabetes. Higher-dose oral semaglutide (25 mg and 50 mg) formulations evaluated in the OASIS program have shown weight loss approaching that of subcutaneous semaglutide. Semaglutide represents a first-in-class efficacy level among GLP-1 receptor agonists for both glycemic control and weight reduction, with a well-characterized safety profile across tens of thousands of clinical trial participants and millions of post-marketing prescriptions.", "lastReviewed": "2026-05-04T11:35:35.395+00:00", "url": "https://www.bodyhackguide.co/compound/semaglutide", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Semaglutide", "alternateName": [ "GLP-1S", "GLP-1 Agonist", "RC-1S", "PEP-1S", "ION-1S", "Ion Peptide Semaglutide", "GLP-1", "Semaglutide", "Sema" ], "description": "Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2. It is a 31-amino-acid peptide analog of human GLP-1(7-37) with two key structural modifications: an alpha-aminoisobutyric acid (Aib) substitution at position 8 that confers resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, and a C18 fatty diacid chain attached via a linker at position 26 (lysine) that enables non-covalent binding to serum albumin. This albumin binding dramatically extends the half-life to approximately 7 days, enabling once-weekly subcutaneous dosing (PMID: 33567185). Semaglutide is FDA-approved under three brand names: Ozempic (subcutaneous injection for type 2 diabetes mellitus), Wegovy (subcutaneous injection for chronic weight management), and Rybelsus (oral tablet for type 2 diabetes). Ozempic was approved in 2017, Wegovy in 2021, and Rybelsus in 2019, making semaglutide one of the most commercially significant pharmaceutical developments of the 2020s. The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program established semaglutide as a transformative obesity treatment. In the STEP 1 trial, participants receiving semaglutide 2.4 mg weekly achieved a mean body weight reduction of 14.9% from baseline at 68 weeks, compared to 2.4% with placebo — a treatment difference of 12.4 percentage points (PMID: 33567185). The STEP 5 trial demonstrated durability of weight loss with continued treatment over 104 weeks, with participants maintaining approximately 15% total body weight loss (PMID: 34170647). The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial was a landmark cardiovascular outcomes study that demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE — cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in overweight or obese individuals without diabetes who received semaglutide 2.4 mg weekly versus placebo over a median follow-up of 39.8 months (PMID: 37351564). This was the first trial to demonstrate cardiovascular benefit of a weight management drug in a non-diabetic population, fundamentally changing the clinical paradigm around obesity pharmacotherapy. Oral semaglutide (Rybelsus) uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) to enable GI absorption of the peptide. Despite low bioavailability (~1%), the oral formulation achieves clinically meaningful glycemic control in type 2 diabetes. Higher-dose oral semaglutide (25 mg and 50 mg) formulations evaluated in the OASIS program have shown weight loss approaching that of subcutaneous semaglutide. Semaglutide represents a first-in-class efficacy level among GLP-1 receptor agonists for both glycemic control and weight reduction, with a well-characterized safety profile across tens of thousands of clinical trial participants and millions of post-marketing prescriptions.", "activeIngredient": "Semaglutide", "administrationRoute": "Subcutaneous (weekly), Oral (daily)", "mechanismOfAction": "GLP-1 Receptor Agonism and cAMP Signaling Semaglutide binds to the GLP-1 receptor (GLP-1R), a class B G-protein coupled receptor expressed on pancreatic beta cells, hypothalamic neurons, gastric smooth muscle, cardiac myocytes, and other tissues. Upon binding, GLP-1R activates adenylyl cyclase via Gs-protein coupling, increasing intracellular cyclic AMP (cAMP) levels. In pancreatic beta cells, elevated cAMP activates protein kinase A (PKA) and exchange protein activated by cAMP (Epac2), which together amplify glucose-dependent insulin secretion through closure of KATP channels, calcium influx, and enhanced exocytosis of insulin granules. Glucose-Dependent Insulin Secretion and Glucagon Suppression A critical safety feature of GLP-1R agonism is its glucose-dependent mechanism: insulin secretion is stimulated only when blood glucose is elevated above fasting levels, minimizing hypoglycemia risk. Simultaneously, semaglutide suppresses glucagon secretion from pancreatic alpha cells in a glucose-dependent manner. This dual effect - enhanced insulin plus reduced glucagon - contributes to significant HbA1c reduction in type 2 diabetes (typically 1.5-1.8% with semaglutide 1.0 mg weekly in the SUSTAIN program). The glucose-lowering effect plateaus at normoglycemia, providing an inherent safety buffer. Hypothalamic Appetite Suppression Semaglutide reaches GLP-1 receptors in the hypothalamic arcuate nucleus and paraventricular nucleus - key brain regions that regulate appetite and energy homeostasis - primarily via circumventricular organs and adjacent fenestrated regions rather than by freely crossing the blood-brain barrier. It activates pro-opiomelanocortin (POMC) neurons that promote satiety and inhibits neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons that drive hunger. It also acts on GLP-1 receptors in the mesolimbic reward system (nucleus accumbens, ventral tegmental area), reducing food reward and hedonic eating. The net effect is reduced food cravings and a shift in food preference toward lower-calorie options. Delayed Gastric Emptying Semaglutide slows gastric emptying, prolonging gastric distension after meals and enhancing satiety signals via vagal afferents. This contributes to reduced caloric intake but also underlies the most common side effects (nausea, vomiting). Gastric emptying delay is most pronounced during dose titration and typically attenuates with continued treatment. Cardiovascular Protection The SELECT trial demonstrated that semaglutide's cardiovascular benefit extends beyond weight loss and glycemic control. Proposed mechanisms include anti-inflammatory effects on the vascular endothelium, reductions in C-reactive protein (CRP) and other markers of systemic inflammation, and improvements in blood pressure and lipid profile - suggesting anti-atherosclerotic activity that is only partly explained by weight loss.", "dosageForm": "vial, pen", "legalStatus": "Not approved for human use (research chemical)", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "How is semaglutide dosed for weight loss?", "acceptedAnswer": { "@type": "Answer", "text": "The Wegovy schedule climbs once a week: 0.25 mg for the first four weeks, then 0.5, 1, 1.7, and 2.4 mg as the maintenance dose, moving up about every four weeks. The 0.25 mg start is there to settle your stomach, not to drive results. Move up only once side effects calm down." } }, { "@type": "Question", "name": "What is the difference between Ozempic and Wegovy?", "acceptedAnswer": { "@type": "Answer", "text": "Same drug, semaglutide, with different branding and approved doses. Ozempic is the type-2-diabetes brand; Wegovy is the weight-management brand and goes to a higher 2.4 mg dose. The molecule is identical." } }, { "@type": "Question", "name": "Why does semaglutide cause nausea?", "acceptedAnswer": { "@type": "Answer", "text": "GLP-1 drugs slow how fast your stomach empties, which is part of how they curb appetite, and that is what drives the nausea. It is dose-related and usually fades. Titrating up slowly is the main way to keep it manageable." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] ```